Radiation vs chemo leads to five times as many secondary cancers

According to a retrospective study published online back in March 2011 in the journal Annals of Oncology, Hodgkin's lymphoma patients being treated with radiotherapy in addition tochemotherapy were several timesmore likely to develop solid second malignant neoplasms (SMN) compared to patients who received only chemotherapy.

Researchers from Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital in Australia looked at a cohort of 142 Hodgkin's patients covering 30 years. What they found was that among the 63 patients who received radiotherapy, 25% had developed SMNs, compared to just 5%of the 79 patients treated with chemotherapy.

This amounts to a five-fold risk of developing SMNs when receiving radiotherapy compared to merely receiving chemotherapy.

At the recent ASTRO meeting, the German Hodgkin Study Group reported that radiotherapy for HL patients should be reserved for certain patients, and not simply part of a sweeping standard guideline of treatment.

Source

Barbaro PM et al. Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy. Ann Oncol. doi: 10.1093/annonc/mdr013

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap